WINTON GROUP Ltd Acquires Shares of 40,976 uniQure N.V. $QURE

WINTON GROUP Ltd bought a new stake in uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 40,976 shares of the biotechnology company’s stock, valued at approximately $2,392,000.

Several other large investors have also made changes to their positions in the company. Swiss National Bank acquired a new position in uniQure in the second quarter valued at about $1,080,000. Sanders Morris Harris LLC bought a new stake in uniQure during the third quarter worth about $5,081,000. Vanguard Group Inc. increased its holdings in shares of uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc raised its stake in shares of uniQure by 6.9% in the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after acquiring an additional 189,029 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Insider Activity at uniQure

In related news, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider directly owned 138,483 shares in the company, valued at $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 12,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer directly owned 226,581 shares of the company’s stock, valued at $2,052,823.86. This represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 81,399 shares of company stock valued at $1,527,645 over the last quarter. 4.79% of the stock is currently owned by corporate insiders.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Multiple broker upgrades and higher price targets — Chardan raised its target and called for strong appreciation, RBC upgraded to Outperform with a $35 target, and Wells Fargo moved the stock to Overweight with a $60 target. These upgrades lift near-term sentiment and institutional interest. Chardan Capital Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock
• Positive Sentiment: Regulatory backdrop improved — market reacted positively after reports of a senior FDA biologics official (CBER director) leaving, which traders interpreted as reducing near-term regulatory friction for AMT‑130 and other gene‑therapy approvals. That narrative helped lift biotech names including QURE. UniQure shares surge 26% on US FDA shakeup even as momentum tumbles: Will new leadership greenlight Huntington’s therapy?
• Positive Sentiment: Analyst reaffirmations and buy ratings (HC Wainwright kept a $70 target) support upside expectations and may sustain buying interest around upcoming catalysts. uniQure: Regulatory Shift and AMT-130 Outlook Drive Reaffirmed Buy Rating and $70 Target
• Neutral Sentiment: High short interest (≈21.2% of float) increases volatility: it can amplify rallies (short-covering) or exacerbate declines if negative news hits. This is a key liquidity/volatility metric to monitor.
• Neutral Sentiment: Wall Street focus ahead of binary drug catalysts — several analyst notes highlight asymmetric upside tied to AMT‑130 and other programs, but outcomes remain binary and trial/regulatory risk is high. uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
• Negative Sentiment: Multiple securities class action filings and law‑firm notices allege disclosures around AMT‑130 and related regulatory matters; several firms have issued investor alerts with an April 13 lead‑plaintiff deadline, creating legal overhang and potential liability risk. uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline
• Negative Sentiment: Regulatory accusations and investor‑rights firm claims — Hagens Berman and others highlight a public rebuke from federal health officials and allegations the company pushed “distorted” data for AMT‑130, which could materially damage credibility and regulatory prospects if substantiated. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman

uniQure Stock Performance

Shares of uniQure stock opened at $18.26 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The firm has a 50 day simple moving average of $21.79 and a 200 day simple moving average of $29.66. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The firm has a market cap of $1.14 billion, a P/E ratio of -5.29 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. Sell-side analysts predict that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on QURE shares. Stifel Nicolaus set a $14.00 price target on uniQure in a research report on Monday, March 2nd. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $11.00 to $35.00 in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Leerink Partners restated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Finally, William Blair reaffirmed a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $41.33.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.